Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

Bill 119 HR 1796, also known as the Sickle Cell Disease Prevention and Treatment Demonstration Program Reauthorization Act, aims to amend the Public Health Service Act in order to reauthorize a program focused on preventing and treating sickle cell disease. Sickle cell disease is a genetic blood disorder that affects red blood cells, causing them to become misshapen and leading to various health complications.

The program in question focuses on demonstrating effective methods for preventing and treating sickle cell disease, with the goal of improving outcomes for individuals living with the condition. By reauthorizing this program, Congress aims to continue supporting research and initiatives aimed at better understanding and addressing sickle cell disease.

This bill is important because sickle cell disease disproportionately affects African Americans and other minority populations, making it a significant public health concern. By reauthorizing this program, Congress is demonstrating its commitment to addressing health disparities and improving outcomes for individuals living with sickle cell disease. Overall, Bill 119 HR 1796 seeks to continue the important work of the Sickle Cell Disease Prevention and Treatment Demonstration Program, with the goal of advancing research, prevention, and treatment efforts related to sickle cell disease.